Corvex, Inc. filed a Form 8-K with the SEC on November 16, 2026, disclosing that it entered into a definitive three-year, $103 million take-or-pay agreement to provide NVIDIA Blackwell computing capacity to a scaled AI inference platform.
Akebia Therapeutics, Inc. filed a Form 8-K on November 16, 2026, disclosing that on November 12, 2026, the company entered into a senior secured term loan facility of up to $140.0 million with Symbiotic Capital Opportunities Holding, L.P. as lender and Symbiotic Capital Agency …
LKQ Corporation filed an 8-K with the SEC on November 16, 2026, disclosing that Senior Vice President and North America segment President John Meyne announced his retirement effective December 31, 2026, and that Paul Shaw has been appointed to succeed him beginning January 1, …
News Corporation filed a Form 8-K on November 16, 2026, reporting the attachment of four exhibits containing share repurchase transaction information provided to the Australian Securities Exchange on dates noted within those exhibits, in connection with the company's ongoing stock repurchase program.
CG Oncology, Inc. filed a Form 8-K on November 16, 2026, disclosing topline data from its Phase 3 PIVOT-006 registrational trial of cretostimogene in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer, along with updated BLA submission timelines.
Everforth, Inc. filed a Form 8-K with the SEC on November 16, 2026, disclosing its intention to commence a private offering of $500 million aggregate principal amount of unsecured senior notes due 2031.
Cadre Holdings, Inc. filed a Form 8-K on November 16, 2026, disclosing that Chief Financial Officer Blaine Browers has resigned effective December 31, 2026, and that Chad Appleby has been appointed interim CFO beginning that same date.
WidePoint Corporation filed a Current Report on Form 8-K on November 16, 2026, disclosing that it conducted an earnings conference call and issued a press release on November 12, 2026, covering financial results for the quarter and nine-month periods ended September 30, 2026.
Arcturus Therapeutics Holdings Inc. filed a Form 8-K on November 16, 2026, disclosing a $50.0 million stock sale to Meiji Seika Pharma Co., Ltd. and concurrent collaboration agreements, including a license and a non-binding memorandum of understanding.
Iroquois Capital Management LLC, Richard Abbe, and Kimberly Page filed Amendment No. 6 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of Common Shares of Clearmind Medicine Inc. as of September 30, 2026.